Navigation Links
Active Biotech presents new pre-clinical data for the 57-57 project,at the 8th World Congress on Inflammation

ng according to plan. This study comprises patients with SLE or rheumatoid arthritis (RA). This is a multi-center study and is being conducted at three hospitals in Sweden - the Karolinska University Hospital in Stockholm, Uppsala University Hospital and Lund University Hospital, in addition to clinics in Russia. Phase II studies are planned to start during 2007.

57-57 has been given the international generic name (INN) paquinimod by the World Health Organization (WHO).

* For further information and to take part of the complete poster "Steroid Sparing Effect of Paquinimod (ABR-215757) in Disease Development of Experimental Lupus in MRLlpr/lpr Mice", please visit www.activebiotech.com .

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB (org. no. 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 20 50


'"/>




Page: 1 2

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Gentiums Defibrotide Seen as Active in Multiple Myeloma
3. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
4. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
5. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
6. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
10. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
11. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
Post Your Comments:
(Date:7/29/2014)... New high priced hepatitis C drugs will increase federal ... to $5.8 billion next year, according to a new ... the Pharmaceutical Care Management Association (PCMA). Milliman projects that ... as 8.6 percent in 2015 as a result of ... The study finds that the majority of new ...
(Date:7/29/2014)... Numotion,s Board of Directors has announced that as ... the company,s new Chief Executive Officer. Swinford ... where he worked primarily for GE Healthcare Services, running businesses ... billion. His most recent position was as President and CEO ... thrilled to join Numotion," said Mike Swinford . "I ...
(Date:7/29/2014)... July 29, 2014  Roche (SIX: RO, ROG; OTCQX: ... Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by ... unique ways Roche is partnering with customers to redefine ... tell us every day that they,re looking for a ... in their labs and offices," said Jack Phillips ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
(Date:7/29/2014)... 30, 2014 Dignity Sciences Limited, a ... of a Phase I trial with DS107G, an oral ... study was a randomized, placebo-controlled, double-blind, single-ascending and multiple ... pharmacokinetics and effect of food on DS107G in healthy ... profile of DGLA following both single and multiple oral ...
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... program was created by a holistic nutritional and functional medicine ... way of overcoming this problem. , Karen suffered from leaky ... so much time to develop this unique treatment. , ... her method, with sufferers from all around the world. The ...
(Date:7/29/2014)... Washington, New York (PRWEB) July 29, 2014 ... to protecting the rights of victims injured by defective ... lawsuit has been filed by plaintiffs in Canada who ... risk of cardiovascular events with the low testosterone ... filed on July 22, 2014 in the Ontario Superior ...
Breaking Medicine News(10 mins):Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3
... Fla., Dec. 13 The Quantum Group,Inc. (Amex: ... it,has completed its registered public offering, raising $13.2 ... it has initiated trading,on the American Stock Exchange ... the symbol "QGP.U." In addition, Quantum common shares,formerly ...
... for the Hospital,s ... State-of-the-Art Cardiothoracic Center, SANTA CLARA, Calif., Dec. ... a new network,infrastructure to support a trust-wide Picture Archiving ... Hospitals, part,of the NHS Foundation Trust in Essex, United ...
... plan services for members, ROCKVILLE, Md., Dec. ... of comprehensive dental plans and administration, has,announced a ... the,nation,s leading integrated health plan provider. GDS will ... and,call center support to Kaiser Permanente Northwest,s 180,000 ...
... NEW YORK, Dec. 13 Getting in shape shouldn,t ... a public health,advocate and veteran of the fitness industry. ... Year, Holland has developed a novel fitness,program to help ... Ease-In Longevity program allows people to "ease into," exercise,going ...
... to 100,000-fold, study finds , , THURSDAY, Dec. 13 (HealthDay News) ... team reports that tiny fibers commonly found in semen drastically ... , According to a study in the Dec. 14 issue ... then ferry it to target cells, increasing its ability to ...
... human spine evolved differently in males and females in ... carrying a baby, according to research spearheaded at The ... are documented for the first time in the Dec. ... adaptation first appeared at least two million years ago, ...
Cached Medicine News:Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 3Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 2Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 3Health News:Fitness Guru Offers Novel Exercise Program and Tips to Stick with Exercise in the New Year 2Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Adapting to pregnancy played key role in human evolution, study shows 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: